Modulation of growth hormone receptor abundance and function: roles for the ubiquitin-proteasome system

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1782, Issue 12, 2008, Pages 785-794

  Frank, Stuart J ^a,b,c   Fuchs, Serge Y ^d  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Downregulation; GHR; Growth hormone; Proteasome; Ubiquitination

Indexed keywords

GAMMA SECRETASE; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; JANUS KINASE 2; PROTEASOME; PROTEASOME INHIBITOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UBIQUITIN;

ENDOCYTOSIS; HORMONE RESISTANCE; HORMONE SENSITIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REVIEW; UBIQUITINATION;

ANIMALS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, SOMATOTROPIN; SIGNAL TRANSDUCTION; UBIQUITIN;

VERTEBRATA;

EID: 56449119800     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2008.06.001     Document Type: Review

References (138)

1. Isaksson O.G., Eden S., and Jansson J.O. Mode of action of pituitary growth hormone on target cells. Annu. Rev. Physiol. 47 (1985) 483-499
2. Bartke A. Minireview: role of the growth hormone/insulin-like growth factor system in mammalian aging. Endocrinology 146 (2005) 3718-3723
3. Melmed S. Medical progress: acromegaly. N. Engl. J. Med. 355 (2006) 2558-2573
4. Vance M.L., and Mauras N. Growth hormone therapy in adults and children. N. Engl. J. Med. 341 (1999) 1206-1216
5. Perry J.K., Mohankumar K.M., Emerald B.S., Mertani H.C., and Lobie P.E. The contribution of growth hormone to mammary neoplasia. J. Mammary Gland. Biol. Neoplasia (2008)
6. Conway-Campbell B.L., Wooh J.W., Brooks A.J., Gordon D., Brown R.J., Lichanska A.M., Chin H.S., Barton C.L., Boyle G.M., Parsons P.G., Jans D.A., and Waters M.J. Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 13331-13336
7. Swanson S.M., and Unterman T.G. The growth hormone-deficient Spontaneous Dwarf rat is resistant to chemically induced mammary carcinogenesis. Carcinogenesis 23 (2002) 977-982
8. Zhang X., Mehta R.G., Lantvit D.D., Coschigano K.T., Kopchick J.J., Green J.E., Hedayat S., Christov K.T., Ray V.H., Unterman T.G., and Swanson S.M. Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling. Carcinogenesis 28 (2007) 143-150
9. Wang Z., Luque R.M., Kineman R.D., Ray V.H., Christov K.T., Lantvit D.D., Shirai T., Hedayat S., Unterman T.G., Bosland M.C., Prins G.S., and Swanson S.M. Disruption of growth hormone signaling retards prostate carcinogenesis in the Probasin/TAg Rat. Endocrinology 149 (2008) 1366-1376
10. Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J. Clin. Endocrinol. Metab. 89 (2004) 1031-1044
11. Zhou Y., Xu B.C., Maheshwari H.G., He L., Reed M., Lozykowski M., Okada S., Cataldo L., Coschigamo K., Wagner T.E., Baumann G., and Kopchick J.J. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13215-13220
12. Bazan J.F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 6934-6938
13. Leung D.W., Spencer S.A., Cachianes G., Hammonds R.G., Collins C., Henzel W.J., Barnard R., Waters M.J., and Wood W.I. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 330 (1987) 537-543
14. Frank S.J., and Messina J.L. Growth hormone receptor. In: Oppenheim J.J., and Feldman M. (Eds). Cytokine Reference On-Line (2002), Academic Press, Harcourt, London, UK 1-21. Website www.academicpress.com/cytokinereference 24-hour free access
15. Carter Su C., Schwartz J., and Smit L.S. Molecular mechanism of growth hormone action. Annu. Rev. Physiol. 58 (1996) 187-207
16. In: Frank S.J., and O'Shea J.J. (Eds). Recent Advances in Cytokine Signal Transduction: Lessons from Growth Hormone and other Cytokines (1999) Greenwich, CT
17. Silvennoinen O., Witthuhn B.A., Quelle F.W., Cleveland J.L., Yi T., and Ihle J.N. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 8429-8433
18. Argetsinger L.S., Campbell G.S., Yang X., Witthuhn B.A., Silvennoinen O., Ihle J.N., and Carter-Su C. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 74 (1993) 237-244
19. Gent J., van Kerkhof P., Roza M., Bu G., and Strous G.J. Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 9858-9863
20. Frank S.J., Gilliland G., Kraft A.S., and Arnold C.S. Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 tyrosine kinase. Endocrinology 135 (1994) 2228-2239
21. Sotiropoulos A., Perrot-Applanat M., Dinerstein H., Pallier A., Postel-Vinay M.C., Finidori J., and Kelly P.A. Distinct cytoplasmic regions of the growth hormone receptor are required for activation of JAK2, mitogen-activated protein kinase, and transcription. Endocrinology 135 (1994) 1292-1298
22. Vanderkuur J.A., Wang X., Zhang L., Campbell G.S., Allevato G., Billestrup N., Norstedt G., and Carter-Su C. Domains of the growth hormone receptor required for association and activation of JAK2 tyrosine kinase. J. Biol. Chem. 269 (1994) 21709-21717
23. Frank S.J., Yi W., Zhao Y., Goldsmith J.F., Gilliland G., Jiang J., Sakai I., and Kraft A.S. Regions of the JAK2 tyrosine kinase required for coupling to the growth hormone receptor. J. Biol. Chem. 270 (1995) 14776-14785
24. Tanner J.W., Chen W., Young R.L., Longmore G.D., and Shaw A.S. The conserved box 1 motif of cytokine receptors is required for association with JAK kinases. J. Biol. Chem. 270 (1995) 6523-6530
25. He K., Wang X., Jiang J., Guan R., Bernstein K.E., Sayeski P.P., and Frank S.J. Janus kinase 2 determinants for growth hormone receptor association, surface assembly, and signaling. Mol. Endocrinol. 17 (2003) 2211-2227
26. Hansen L.H., Wang X., Kopchick J.J., Bouchelouche P., Nielsen J.H., Galsgaard E.D., and Billestrup N. Identification of tyrosine residues in the intracellular domain of the growth hormone receptor required for transcriptional signaling and Stat5 activation. J. Biol. Chem. 271 (1996) 12669-12673
27. Smit L.S., Meyer D.J., Billestrup N., Norstedt G., Schwartz J., and Carter-Su C. The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH. Mol. Endocrinol. 10 (1996) 519-533
28. Sotiropoulos A., Moutoussamy S., Renaudie F., Clauss M., Kayser C., Gouilleux F., Kelly P.A., and Finidori J. Differential activation of Stat3 and Stat5 by distinct regions of the growth hormone receptor. Mol. Endocrinol. 10 (1996) 998-1009
29. Wang X., Darus C.J., Xu B.C., and Kopchick J.J. Identification of growth hormone receptor (GHR) tyrosine residues required for GHR phosphorylation and JAK2 and STAT5 activation. Mol. Endocrinol. 10 (1996) 1249-1260
30. Yi W., Kim S.O., Jiang J., Park S.H., Kraft A.S., Waxman D.J., and Frank S.J. Growth hormone receptor cytoplasmic domain differentially promotes tyrosine phosphorylation of signal transducers and activators of transcription 5b and 3 by activated JAK2 kinase. Mol. Endocrinol. 10 (1996) 1425-1443
31. Bergad P.L., Shih H.M., Towle H.C., Schwarzenberg S.J., and Berry S.A. Growth hormone induction of hepatic serine protease inhibitor 2.1 transcription is mediated by a Stat5-related factor binding synergistically to two gamma-activated sites. J. Biol. Chem. 270 (1995) 24903-24910
32. Davey H.W., McLachlan M.J., Wilkins R.J., Hilton D.J., and Adams T.E. STAT5b mediates the GH-induced expression of SOCS-2 and SOCS-3 mRNA in the liver. Mol. Cell Endocrinol. 158 (1999) 111-116
33. Davey H.W., Xie T., McLachlan M.J., Wilkins R.J., Waxman D.J., and Grattan D.R. STAT5b is required for GH-induced liver IGF-I gene expression. Endocrinology 142 (2001) 3836-3841
34. Udy G.B., Towers R.P., Snell R.G., Wilkins R.J., Park S.H., Ram P.A., Waxman D.J., and Davey H.W. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 7239-7244
35. Ooi G.T., Hurst K.R., Poy M.N., Rechler M.M., and Boisclair Y.R. Binding of STAT5a and STAT5b to a single element resembling a gamma-interferon-activated sequence mediates the growth hormone induction of the mouse acid-labile subunit promoter in liver cells. Molecular. Endocrinology. 12 (1998) 675-687
36. Woelfle J., Billiard J., and Rotwein P. Acute control of insulin-like growth factor-I gene transcription by growth hormone through Stat5b. J. Biol. Chem. 278 (2003) 22696-22702
37. Moller C., Hansson A., Enberg B., Lobie P.E., and Norstedt G. Growth hormone (GH) induction of tyrosine phosphorylation and activation of mitogen-activated protein kinases in cells transfected with rat GH receptor cDNA. J. Biol. Chem. 267 (1992) 23403-23408
38. Argetsinger L.S., Hsu G.W., Myers M.G.J., Billestrup N., White M.F., and Carter-Su C. Growth hormone, interferon-gamma, and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate-1. J. Biol. Chem. 270 (1995) 14685-14692
39. Argetsinger L.S., Norstedt G., Billestrup N., White M.F., and Carter-Su C. Growth hormone, interferon-gamma, and leukemia inhibitory factor utilize insulin receptor substrate-2 in intracellular signaling. J. Biol. Chem. 271 (1996) 29415-29421
40. Hodge C., Liao J., Stofega M., Guan K., Carter-Su C., and Schwartz J. Growth hormone stimulates phosphorylation and activation of elk-1 and expression of c-fos, egr-1, and junB through activation of extracellular signal-regulated kinases 1 and 2. J. Biol. Chem. 273 (1998) 31327-31336
41. Liang L., Zhou T., Jiang J., Pierce J.H., Gustafson T.A., and Frank S.J. Insulin receptor substrate-1 enhances growth hormone-induced proliferation. Endocrinology 140 (1999) 1972-1983
42. Kim S.O., Houtman J.C., Jiang J., Ruppert J.M., Bertics P.J., and Frank S.J. Growth hormone-induced alteration in ErbB-2 phosphorylation status in 3T3-F442A fibroblasts. J. Biol. Chem. 274 (1999) 36015-36024
43. Huang Y., Chang Y., Wang X., Jiang J., and Frank S.J. Growth hormone alters epidermal growth factor receptor binding affinity via activation of ERKs in 3T3-F442A cells. Endocrinology 145 (2004) 3297-3306
44. Huang Y., Kim S.O., Jiang J., and Frank S.J. Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling. J. Biol. Chem. 278 (2003) 18902-18913
45. Costoya J.A., Finidori J., Moutoussamy S., Searis R., Devesa J., and Arce V.M. Activation of growth hormone receptor delivers an antiapoptotic signal: evidence for a role of Akt in this pathway. Endocrinology 140 (1999) 5937-5943
46. Jeay S., Sonenshein G.E., Kelly P.A., Postel-Vinay M.C., and Baixeras E. Growth hormone exerts antiapoptotic and proliferative effects through two different pathways involving nuclear factor-kappaB and phosphatidylinositol 3-kinase. Endocrinology 142 (2001) 147-156
47. Kilgour E., Gout I., and Anderson N.G. Requirement for phosphoinositide 3-OH kinase in growth hormone signalling to the mitogen-activated protein kinase and p70s6k pathways. Biochem. J. 315 (1996) 517-522
48. MacKenzie S.J., Yarwood S.J., Peden A.H., Bolger G.B., Vernon R.G., and Houslay M.D. Stimulation of p70S6 kinase via a growth hormone-controlled phosphatidylinositol 3-kinase pathway leads to the activation of a PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadipocytes. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 3549-3554
49. Liang L., Jiang J., and Frank S.J. Insulin receptor substrate-1-mediated enhancement of growth hormone-induced mitogen-activated protein kinase activation. Endocrinology 141 (2000) 3328-3336
50. Schwartzbauer G., and Menon R.K. Regulation of growth hormone receptor gene expression. Mol. Genet. Metab. 63 (1998) 243-253
51. Talamantes F., and Ortiz R. Structure and regulation of expression of the mouse GH receptor. J. Endocrinol. 175 (2002) 55-59
52. Edens A., and Talamantes F. Alternative processing of growth hormone receptor transcripts. Endocr. Rev. 19 (1998) 559-582
53. Landis C.A., Harsh G., Lyons J., Davis R.L., McCormick F., and Bourne H.R. Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. J. Clin. Endocrinol. Metab. 71 (1990) 1416-1420
54. Landis C.A., Masters S.B., Spada A., Pace A.M., Bourne H.R., and Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340 (1989) 692-696
55. Lyons J., Landis C.A., Harsh G., Vallar L., Grunewald K., Feichtinger H., Duh Q.Y., Clark O.H., Kawasaki E., Bourne H.R., et al. Two G protein oncogenes in human endocrine tumors. Science 249 (1990) 655-659
56. Spada A., Arosio M., Bochicchio D., Bazzoni N., Vallar L., Bassetti M., and Faglia G. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J. Clin. Endocrinol. Metab. 71 (1990) 1421-1426
57. Asa S.L., Digiovanni R., Jiang J., Ward M.L., Loesch K., Yamada S., Sano T., Yoshimoto K., Frank S.J., and Ezzat S. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res. 67 (2007) 7505-7511
58. Chia D.J., Subbian E., Buck T.M., Hwa V., Rosenfeld R.G., Skach W.R., Shinde U., and Rotwein P. Aberrant folding of a mutant Stat5b causes growth hormone insensitivity and proteasomal dysfunction. J. Biol. Chem. 281 (2006) 6552-6558
59. Kofoed E.M., Hwa V., Little B., Woods K.A., Buckway C.K., Tsubaki J., Pratt K.L., Bezrodnik L., Jasper H., Tepper A., Heinrich J.J., and Rosenfeld R.G. Growth hormone insensitivity associated with a STAT5b mutation. N. Engl. J. Med. 349 (2003) 1139-1147
60. Brown R.J., Adams J.J., Pelekanos R.A., Wan Y., McKinstry W.J., Palethorpe K., Seeber R.M., Monks T.A., Eidne K.A., Parker M.W., and Waters M.J. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat. Struct. Mol. Biol. 12 (2005) 814-821
61. van den Eijnden M.J., Lahaye L.L., and Strous G.J. Disulfide bonds determine growth hormone receptor folding, dimerisation and ligand binding. J. Cell. Sci. 119 (2006) 3078-3086
62. He K., Loesch K., Cowan J.W., Li X., Deng L., Wang X., Jiang J., and Frank S.J. JAK2 enhances the stability of the mature GH receptor. Endocrinology 145 (2005) 4755-4765
63. Loesch K., Deng L., Wang X., He K., Jiang J., and Frank S.J. Endoplasmic reticulum-associated degradation of growth hormone receptor in Janus kinase 2-deficient cells. Endocrinology 148 (2007) 5955-5965
64. Silva C.M., Day R.N., Weber M.J., and Thorner M.O. Human growth hormone (GH) receptor is characterized as the 134-kilodalton tyrosine-phosphorylated protein activated by GH treatment in IM-9 cells. Endocrinology 133 (1993) 2307-2312
65. Wang X., He K., Gerhart M., Huang Y., Jiang J., Paxton R.J., Yang S., Lu C., Menon R.K., Black R.A., Baumann G., and Frank S.J. Metalloprotease-mediated GH receptor proteolysis and GHBP shedding. Determination of extracellular domain stem region cleavage site. J. Biol. Chem. 277 (2002) 50510-50519
66. Loesch K., Deng L., Cowan J.W., Wang X., He K., Jiang J., Black R.A., and Frank S.J. JAK2 influences growth hormone receptor metalloproteolysis. Endocrinology 147 (2006) 2839-2849
67. Romisch K. Endoplasmic reticulum-associated degradation. Annu. Rev. Cell. Dev. Biol. 21 (2005) 435-456
68. Ahner A., and Brodsky J.L. Checkpoints in ER-associated degradation: excuse me, which way to the proteasome?. Trends. Cell. Biol. 14 (2004) 474-478
69. Schmitz A., and Herzog V. Endoplasmic reticulum-associated degradation: exceptions to the rule. Eur. J. Cell. Biol. 83 (2004) 501-509
70. Gauzzi M.C., Barbieri G., Richter M.F., Uze G., Ling L., Fellous M., and Pellegrini S. The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 11839-11844
71. Ragimbeau J., Dondi E., Alcover A., Eid P., Uze G., and Pellegrini S. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO. J. 22 (2003) 537-547
72. Royer Y., Staerk J., Costuleanu M., Courtoy P.J., and Constantinescu S.N. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J. Biol. Chem. 280 (2005) 27251-27261
73. Radtke S., Hermanns H.M., Haan C., Schmitz-Van De Leur H., Gascan H., Heinrich P.C., and Behrmann I. Novel role of Janus kinase 1 in the regulation of oncostatin M receptor surface expression. J. Biol. Chem. 277 (2002) 11297-11305
74. Radtke S., Jorissen A., de Leur H.S., Heinrich P.C., and Behrmann I. Three dileucine-like motifs within the interbox1/2 region of the human oncostatin M receptor prevent efficient surface expression in the absence of an associated Janus kinase. J. Biol. Chem. 281 (2006) 4024-4034
75. Huang L.J., Constantinescu S.N., and Lodish H.F. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol. Cell. 8 (2001) 1327-1338
76. Hofmann S.R., Lam A.Q., Frank S., Zhou Y.J., Ramos H.L., Kanno Y., Agnello D., Youle R.J., and O'Shea J.J. Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited. Mol. Cell. Biol. 24 (2004) 5039-5049
77. Moorthy A.K., Savinova O.V., Ho J.Q., Wang V.Y., Vu D., and Ghosh G. The 20S proteasome processes NF-kappaB1 p105 into p50 in a translation-independent manner. EMBO. J. 25 (2006) 1945-1956
78. Cohen S., Lahav-Baratz S., and Ciechanover A. Two distinct ubiquitin-dependent mechanisms are involved in NF-kappaB p105 proteolysis. Biochem. Biophys. Res. Commun. 345 (2006) 7-13
79. Liu C.W., Corboy M.J., DeMartino G.N., and Thomas P.J. Endoproteolytic activity of the proteasome. Science 299 (2003) 408-411
80. Alele J., Jiang J., Goldsmith J.F., Yang X., Maheshwari H.G., Black R.A., Baumann G., and Frank S.J. Blockade of growth hormone receptor shedding by a metalloprotease inhibitor. Endocrinology 139 (1998) 1927-1935
81. Wang X., He K., Gerhart M., Jiang J., Paxton R.J., Menon R.K., Black R.A., Baumann G., and Frank S.J. Reduced proteolysis of rabbit growth hormone (GH) receptor substituted with mouse GH receptor cleavage site. Mol. Endocrinol. 17 (2003) 1931-1943
82. Baumann G. Growth hormone binding protein 2001. J. Pediatr. Endocrinol. Metab. 14 (2001) 355-375
83. Baumann G., and Frank S.J. Metalloproteinases and the modulation of GH signaling. J. Endocrinol. 174 (2002) 361-368
84. Guan R., Zhang Y., Jiang J., Baumann C.A., Black R.A., Baumann G., and Frank S.J. Phorbol ester- and growth factor-induced growth hormone (GH) receptor proteolysis and GH-binding protein shedding: relationship to GH receptor down-regulation. Endocrinology 142 (2001) 1137-1147
85. Zhang Y., Guan R., Jiang J., Kopchick J.J., Black R.A., Baumann G., and Frank S.J. Growth hormone (GH)-induced dimerization inhibits phorbol ester-stimulated GH receptor proteolysis. J. Biol. Chem. 276 (2001) 24565-24573
86. Jiang J., Wang X., He K., Li X., Chen C., Sayeski P.P., Waters M.J., and Frank S.J. A Conformationally-sensitive GHR (Growth Hormone (GH) Receptor) antibody: impact on GH signaling and GHR proteolysis. Mol. Endocrinol. 18 (2004) 2981-2996
87. Cowan J.W., Wang X., Guan R., He K., Jiang J., Baumann G., Black R.A., Wolfe M.S., and Frank S.J. Growth hormone receptor is a target for presenilin-dependent gamma-secretase cleavage. J. Biol. Chem. 280 (2005) 19331-19342
88. Zhang Y., Jiang J., Black R.A., Baumann G., and Frank S.J. TACE is a growth hormone binding protein sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) growth hormone receptor proteolysis and GHBP generation. Endocrinology 141 (2000) 4324-4348
89. Wang X., Jiang J., Warram J., Baumann G., Gan Y., Menon R.K., Denson L.A., Zinn K.R., and Frank S.J. Endotoxin-induced proteolytic reduction in hepatic growth hormone receptor: a novel mechanism for GH insensitivity. Mol. Endocrinol. (2008)
90. Wolfe M.S., and Kopan R. Intramembrane proteolysis: theme and variations. Science 305 (2004) 1119-1123
91. Strous G.J., and van Kerkhof P. The ubiquitin-proteasome pathway and the regulation of growth hormone receptor availability. Mol. Cell. Endocrinol. 197 (2002) 143-151
92. van Kerkhof P., Govers R., Alves dos Santos C.M., and Strous G.J. Endocytosis and degradation of the growth hormone receptor are proteasome-dependent. J. Biol. Chem. 275 (2000) 1575-1580
93. van Kerkhof P., Smeets M., and Strous G.J. The ubiquitin-proteasome pathway regulates the availability of the GH receptor. Endocrinology 143 (2002) 1243-1252
94. van Kerkhof P., Sachse M., Klumperman J., and Strous G.J. Growth hormone receptor ubiquitination coincides with recruitment to clathrin-coated membrane domains. J. Biol. Chem. 276 (2001) 3778-3784
95. Strous G.J., van Kerkhof P., Govers R., Ciechanover A., and Schwartz A.L. The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor. EMBO. J. 15 (1996) 3806-3812
96. Govers R., ten Broeke T., van Kerkhof P., Schwartz A.L., and Strous G.J. Identification of a novel ubiquitin conjugation motif, required for ligand-induced internalization of the growth hormone receptor. EMBO J. 18 (1999) 28-36
97. Allevato G., Billestrup N., Goujon L., Galsgaard E.D., Norstedt G., Postel-Vinay M.C., Kelly P.A., and Nielsen J.H. Identification of phenylalanine 346 in the rat growth hormone receptor as being critical for ligand-mediated internalization and down-regulation. J. Biol. Chem. 270 (1995) 17210-17214
98. Roupas P., and Herington A.C. Intracellular processing of growth hormone receptors by adipocytes in primary culture. Mol. Cell. Endocrinol. 57 (1988) 93-99
99. Lesniak M.A., and Roth J. Regulation of receptor concentration by homologous hormone. Effect of human growth hormone on its receptor in IM-9 lymphocytes. J. Biol. Chem. 251 (1976) 3720-3729
100. Hizuka N., Gorden P., Lesniak M.A., Van Obberghen E., Carpentier J.L., and Orci L. Polypeptide hormone degradation and receptor regulation are coupled to ligand internalization. A direct biochemical and morphologic demonstration. J. Biol. Chem. 256 (1981) 4591-4597
101. Takagi K., Saito Y., and Sawada J.I. Proteasomes are involved in the constitutive degradation of growth hormone receptors. Biol. Pharm. Bull. 24 (2001) 744-748
102. Moulin S., Bouzinba-Segard H., Kelly P.A., and Finidori J. Jak2 and proteasome activities control the availability of cell surface growth hormone receptors during ligand exposure. Cell. Signal. 15 (2003) 47-55
103. Saito Y., Teshima R., Yamazaki T., Ikebuchi H., and Sawada J. Ligand-induced internalization and phosphorylation-dependent degradation of growth hormone receptor in human IM-9 cells. Mol. Cell. Endocrinol. 106 (1994) 67-74
104. Alves dos Santos C.M., ten Broeke T., and Strous G.J. Growth hormone receptor ubiquitination, endocytosis, and degradation are independent of signal transduction via Janus kinase 2. J. Biol. Chem. 276 (2001) 32635-32641
105. Deng L., He K., Wang X., Yang N., Thangavel C., Jiang J., Fuchs S.Y., and Frank S.J. Determinants of growth hormone receptor down-regulation. Mol. Endocrinol. 21 (2007) 1537-1551
106. Burke P., Schooler K., and Wiley H.S. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol. Biol. Cell. 12 (2001) 1897-1910
107. Moutoussamy S., Renaudie F., Lago F., Kelly P.A., and Finidori J. Grb10 identified as a potential regulator of growth hormone (GH) signaling by cloning of GH receptor target proteins. J. Biol. Chem. 273 (1998) 15906-15912
108. Stofega M.R., Herrington J., Billestrup N., and Carter-Su C. Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B. Mol. Endocrinol. 14 (2000) 1338-1350
109. Ram P.A., and Waxman D.J. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J. Biol. Chem. 274 (1999) 35553-35561
110. Du L., Frick G.P., Tai L.R., Yoshimura A., and Goodman H.M. Interaction of the growth hormone receptor with cytokine-induced Src homology domain 2 protein in rat adipocytes. Endocrinology 144 (2003) 868-876
111. Kim S.O., Jiang J., Yi W., Feng G.S., and Frank S.J. Involvement of the Src homology 2-containing tyrosine phosphatase SHP-2 in growth hormone signaling. J. Biol. Chem. 273 (1998) 2344-2354
112. Zhang J.G., Farley A., Nicholson S.E., Willson T.A., Zugaro L.M., Simpson R.J., Moritz R.L., Cary D., Richardson R., Hausmann G., Kile B.J., Kent S.B., Alexander W.S., Metcalf D., Hilton D.J., Nicola N.A., and Baca M. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 2071-2076
113. Landsman T., and Waxman D.J. Role of the cytokine-induced SH2 domain-containing protein CIS in growth hormone receptor internalization. J. Biol. Chem. 280 (2005) 37471-37480
114. Kumar K.G., Tang W., Ravindranath A.K., Clark W.A., Croze E., and Fuchs S.Y. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO. J. 22 (2003) 5480-5490
115. Kumar K.G., Krolewski J.J., and Fuchs S.Y. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. J. Biol. Chem. 279 (2004) 46614-46620
116. Li Y., Kumar K.G., Tang W., Spiegelman V.S., and Fuchs S.Y. Negative regulation of prolactin receptor stability and signaling mediated by SCF(beta-TrCP) E3 ubiquitin ligase. Mol. Cell. Biol. 24 (2004) 4038-4048
117. Li Y., Clevenger C.V., Minkovsky N., Kumar K.G., Raghunath P.N., Tomaszewski J.E., Spiegelman V.S., and Fuchs S.Y. Stabilization of prolactin receptor in breast cancer cells. Oncogene (2005)
118. Meyer L., Deau B., Forejtnikova H., Dumenil D., Margottin-Goguet F., Lacombe C., Mayeux P., and Verdier F. Beta-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation. Blood (2007)
119. Marijanovic Z., Ragimbeau J., Kumar K.G., Fuchs S.Y., and Pellegrini S. TYK2 activity promotes ligand-induced IFNAR1 proteolysis. Biochem. J. 397 (2006) 31-38
120. Swaminathan G., Varghese B., Thangavel C., Carbone C.J., Plotnikov A., Kumar K.G., Jablonski E.M., Clevenger C.V., Goffin V., Deng L., Frank S.J., and Fuchs S.Y. Prolactin stimulates ubiquitination, initial internalization, and degradation of its receptor via catalytic activation of Janus kinase 2. J. Endocrinol. 196 (2008) R1-R7
121. Walrafen P., Verdier F., Kadri Z., Chretien S., Lacombe C., and Mayeux P. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 105 (2005) 600-608
122. van Kerkhof P., Putters J., and Strous G.J. The ubiquitin ligase SCF(betaTrCP) regulates the degradation of the growth hormone receptor. J. Biol. Chem. 282 (2007) 20475-20483
123. d'Azzo A., Bongiovanni A., and Nastasi T. E3 ubiquitin ligases as regulators of membrane protein trafficking and degradation. Traffic 6 (2005) 429-441
124. Sigismund S., Polo S., and Di Fiore P.P. Signaling through monoubiquitination. Curr. Top. Microbiol. Immunol. 286 (2004) 149-185
125. Haglund K., Sigismund S., Polo S., Szymkiewicz I., Di Fiore P.P., and Dikic I. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat. Cell. Biol. 5 (2003) 461-466
126. Raiborg C., Rusten T.E., and Stenmark H. Protein sorting into multivesicular endosomes. Curr. Opin. Cell. Biol. 15 (2003) 446-455
127. Polo S., Confalonieri S., Salcini A.E., and Di Fiore P.P. EH and UIM: endocytosis and more. Sci. STKE. (2003) re17
128. Hicke L., and Dunn R. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu. Rev. Cell. Dev. Biol. 19 (2003) 141-172
129. Govers R., van Kerkhof P., Schwartz A.L., and Strous G.J. Di-leucine-mediated internalization of ligand by a truncated growth hormone receptor is independent of the ubiquitin conjugation system. J. Biol. Chem. 273 (1998) 16426-16433
130. Strous G.J., van Kerkhof P., Govers R., Rotwein P., and Schwartz A.L. Growth hormone-induced signal tranduction depends on an intact ubiquitin system. J. Biol. Chem. 272 (1997) 40-43
131. Govers R., van Kerkhof P., Schwartz A.L., and Strous G.J. Linkage of the ubiquitin-conjugating system and the endocytic pathway in ligand-induced internalization of the growth hormone receptor. Embo. J. 16 (1997) 4851-4858
132. Alves dos Santos C.M., van Kerkhof P., and Strous G.J. The signal transduction of the growth hormone receptor is regulated by the ubiquitin/proteasome system and continues after endocytosis. J. Biol. Chem. 276 (2001) 10839-10846
133. van Kerkhof P., and Strous G.J. The ubiquitin-proteasome pathway regulates lysosomal degradation of the growth hormone receptor and its ligand. Biochem. Soc. Trans. 29 (2001) 488-493
134. Sachse M., van Kerkhof P., Strous G.J., and Klumperman J. The ubiquitin-dependent endocytosis motif is required for efficient incorporation of growth hormone receptor in clathrin-coated pits, but not clathrin-coated lattices. J. Cell. Sci. 114 (2001) 3943-3952
135. Gent J., Van Den Eijnden M., Van Kerkhof P., and Strous G.J. Dimerization and signal transduction of the growth hormone receptor. Mol. Endocrinol. 17 (2003) 967-975
136. Strous G.J., and Gent J. Dimerization, ubiquitylation and endocytosis go together in growth hormone receptor function. FEBS. Lett. 529 (2002) 102-109
137. Kumar K.G., Barriere H., Carbone C.J., Liu J., Swaminathan G., Xu P., Li Y., Baker D.P., Peng J., Lukacs G.L., and Fuchs S.Y. Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis. J. Cell. Biol. 179 (2007) 935-950
138. Cadwell K., and Coscoy L. Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase. Science 309 (2005) 127-130